NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class (Descending) | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
69945-0452-20 | 69945-0452 | sodium iodide i 131 | SODIUM IODIDE I 131 | 1.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Oct. 27, 2015 | July 1, 2018 | No Longer Used |
69945-0452-50 | 69945-0452 | sodium iodide i 131 | SODIUM IODIDE I 131 | 1.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Oct. 27, 2015 | July 1, 2018 | No Longer Used |
69945-0452-75 | 69945-0452 | sodium iodide i 131 | SODIUM IODIDE I 131 | 1.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | Oct. 27, 2015 | July 1, 2018 | No Longer Used |
17156-0524-01 | 17156-0524 | Strontium Chloride Sr-89 | Metastron | 1.0 mCi/mL | Ancillary Therapy | Radiopharmaceutical | Strontium Sr 89 | Intravenous | June 18, 1993 | Jan. 10, 2019 | In Use |
11994-0016-01 | 11994-0016 | samarium Sm 153 lexidronam | Quadramet | 50.0 mCi/mL | Ancillary Therapy | Radiopharmaceutical | Samarium Sm 153 | Intravenous | May 19, 1997 | In Use | |
69488-0010-61 | 69488-0010 | Lutetium Lu 177 vipivotide tetraxetan | PLUVICTO | 27.0 mCi/mL | Radiopharmaceutical | Radiopharmaceutical | PSMA | Intravenous | March 23, 2022 | In Use | |
65174-0880-00 | 65174-0880 | Sodium Iodide I 131 | HICON | 1000.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | April 7, 2003 | In Use | |
65174-0880-25 | 65174-0880 | Sodium Iodide I 131 | HICON | 1000.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | April 7, 2003 | In Use | |
65174-0880-50 | 65174-0880 | Sodium Iodide I 131 | HICON | 1000.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | April 7, 2003 | In Use | |
50419-0208-01 | 50419-0208 | Radium Ra 223 dichloride | Xofigo | 30.0 uCi/mL | Chemotherapy | Radiopharmaceutical | Radium 223 | Intravenous | May 20, 2013 | In Use | |
71258-0015-02 | 71258-0015 | iobenguane I-131 | Azedra | 15.0 mCi/mL | Chemotherapy | Radiopharmaceutical | I 131 | Intravenous | July 30, 2018 | In Use | |
71258-0015-22 | 71258-0015 | iobenguane I-131 | Azedra | 15.0 mCi/mL | Chemotherapy | Radiopharmaceutical | I 131 | Intravenous | July 30, 2018 | In Use | |
68152-0104-04 | 68152-0104 | Ibritumomab Tiuxetan | Zevalin | Immunotherapy | Radioimmunotherapy | CD20 | Feb. 19, 2002 | Dec. 3, 2011 | No Longer Used | ||
00007-3260-31 | 00007-3260 | Tositumomab | Bexxar | Immunotherapy | Radioimmunotherapy | CD20 | July 15, 2009 | Nov. 28, 2014 | No Longer Used | ||
00007-3260-36 | 00007-3260 | Tositumomab | Bexxar | Immunotherapy | Radioimmunotherapy | CD20 | July 15, 2009 | Nov. 28, 2014 | No Longer Used | ||
00007-3261-01 | 00007-3261 | Tositumomab, Iodine I-131 | Bexxar Dosimetric | Immunotherapy | Radioimmunotherapy | CD20 | July 15, 2009 | Feb. 13, 2014 | No Longer Used | ||
00007-3262-01 | 00007-3262 | Tositumomab, Iodine I-131 | Bexxar Therapeutic | Immunotherapy | Radioimmunotherapy | CD20 | July 15, 2009 | Feb. 20, 2014 | No Longer Used | ||
68152-0103-03 | 68152-0103 | Ibritumomab Tiuxetan | Zevalin | Immunotherapy | Radioimmunotherapy | CD20 | Feb. 19, 2002 | Oct. 26, 2020 | In Use | ||
55513-0488-02 | 55513-0488 | Sotorasib | LUMAKRAS | 120.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | May 28, 2021 | In Use | |
55513-0488-24 | 55513-0488 | Sotorasib | LUMAKRAS | 120.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | May 28, 2021 | In Use | |
55513-0488-96 | 55513-0488 | Sotorasib | LUMAKRAS | 120.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | May 28, 2021 | In Use | |
80739-0812-12 | 80739-0812 | Adagrasib | KRAZATI | 200.0 mg/1 | Immunotherapy | RAS Inhibitor | KRAS G12C | Oral | Dec. 12, 2022 | In Use | |
80739-0812-18 | 80739-0812 | Adagrasib | KRAZATI | 200.0 mg/1 | Immunotherapy | RAS Inhibitor | KRAS G12C | Oral | Dec. 12, 2022 | In Use | |
55513-0504-50 | 55513-0504 | Sotorasib | LUMAKRAS | 320.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | Feb. 2, 2023 | In Use | |
55513-0512-60 | 55513-0512 | Sotorasib | LUMAKRAS | 240.0 mg/1 | Chemotherapy | RAS Inhibitor | KRAS G12C | Oral | June 27, 2024 | In Use |
Found 10,000 results in 4 milliseconds — Export these results